在阿片类药物剂量升级后恶心和吐频率的分析及其危险因素:单中心回顾性观察性研究
Yoshihiro Yamamoto1, Seiji Yamamoto2, Taiga Tsuge2,3
1Departments of Pharmacy, Komaki City Hospital, Komaki, Aichi, Japan.
Journal of palliative medicine
|September 21, 2023
概括
在癌症患者的阿片类药物剂量升级期间,阿片类药物诱导的恶心和吐 (OINV) 经常发生. 糟糕的表现状况和先前的恶心病史是关键的风险因素,需要谨慎监测.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 阿片类药物诱导的恶心和吐 (OINV) 是阿片类药物治疗的常见副作用.
- 在阿片类药物剂量升级期间OINV的发病率和风险因素仍然不完全理解.
研究的目的:
- 确定住院癌症患者在阿片类药物剂量升级期间OINV的频率.
- 在剂量升级期间确定与OINV发展相关的患者特异性风险因素.
主要方法:
- 从132名住院癌症患者的医疗记录进行了回顾性分析,这些患者接受了增加的口服氧化.
- 评估包括人口统计,阿片类药物剂量,并发症,先前恶心史和抗药使用等因素.
主要成果:
- 在阿片类药物剂量升级期间,OINV发生在43.9%的患者中.
- 首次阿片类药物引入时的表现状况 (≥2) 和恶心病史是OINV的重要风险因素.
- 在剂量升级过程中,预防性抗emetics不能完全预防OINV.
结论:
- 阿片类药物剂量升级与OINV的高发病率有关.
- 性能状况较差且有阿片类药物诱导的恶心病史的患者的风险增加.
- 在癌症患者的阿片类药物剂量调整期间,对OINV的持续监测至关重要.
更多相关视频
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
300
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
300
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
184
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
184
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
320
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
320
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
231
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
231
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
230
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
230
Analgesia and Pain Management
649
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
649


